Gilead Sciences Inc (GILD.O)
13 Jul 2018
ZURICH, June 29 Rival cancer cell therapies from Swiss drugmaker Novartis and U.S.-based Gilead Sciences won a key recommendation from a European Medicines Agency panel, likely clearing their way for approval within months.
June 29 - Rival cancer cell therapies from Swiss drugmaker Novartis and U.S.-based Gilead Sciences won a key recommendation from a European Medicines Agency panel, likely clearing their way for approval within a couple of months.
LONDON, June 20 GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.
June 14 GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field.
* U.S. FOOD AND DRUG ADMINISTRATION APPROVES EXPANDED INDICATION FOR TRUVADA® (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE) FOR REDUCING THE RISK OF ACQUIRING HIV-1 IN ADOLESCENTS
* KITE ANNOUNCES NEW WORLDWIDE FACILITIES AND EXPANDED COLLABORATION WITH NATIONAL CANCER INSTITUTE TO SUPPORT CELL THERAPY PIPELINE
A federal appeals court on Friday tossed a lawsuit brought by a nonprofit arguing Gilead Sciences Inc patents relating to several of its HIV/AIDS drugs are invalid.
BRIEF-Gilead Sciences Board Has Declared A Cash Dividend Of $0.57 Per Share Of Common Stock For Q2 Of 2018
* GILEAD SCIENCES INC - BOARD OF DIRECTORS HAS DECLARED A CASH DIVIDEND OF $0.57 PER SHARE OF COMMON STOCK FOR Q2 OF 2018 Source text for Eikon: Further company coverage:
* GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS
Gilead Sciences Inc reported a lower quarterly profit on Tuesday as sales of its flagship hepatitis C drugs fell by a greater-than-expected 59 percent, sending shares of the biotechnology company down 5 percent.
|Pfizer Inc. (PFE.N)||$37.53||+0.01|
|Novartis AG (NOVN.S)||CHF79.16||+0.22|
|Merck & Co., Inc. (MRK.N)||$62.89||+0.23|
|Roche Holding Ltd. (ROG.S)||CHF232.70||+2.25|
|Roche Holding Ltd. (RO.S)||CHF237.80||+2.60|
|GlaxoSmithKline plc (GSK.L)||1,576.00||-0.60|
|Actelion Ltd (ATLN.S)||--||--|
|United Therapeutics Corporation (UTHR.OQ)||$124.74||+0.60|
|ViiV Healthcare Ltd (IPO-VIHL.L)||--||--|
|AbbVie Inc (ABBV.N)||$96.63||+1.02|